Pooled Funds to Fight Neglected Diseases: Assessing New Models to Finance Global Health R&D
Center for Global Health R&D Policy Assessment
Can a pooled fund help improve funding flows to global health R&D projects? Could it bring new funders to the table?
The Center’s assessment of pooled funding for global health R&D, which was led by technical consultants Cheri Grace and Mark Pearson, addresses these two critical questions of more and “better” money. The analysis considers the three most prominent pooled funding proposals: the Industry R&D Facilitation Fund (IRFF), the Fund for Research in Neglected Diseases (FRIND), and the Product Development Partnership Financing Facility (PDP-FF).
Drawing on literature, illustrative modeling, consultations with experts and the experiences of other pooled funding mechanisms outside of R&D, this assessment examines whether these proposals are likely to improve research for global health and what important design concerns lie ahead.
The Center's brief "Pooled Funds to Fight Neglected Diseases: Assessing New Models to Finance Global Health R&D" comprises an executive summary and main findings from the assessment. In addition, the full technical background report includes the authors' full analysis.
To read our consultation draft, click here.
Since the release of this report, Novartis has submitted a revised proposal for FRIND to the WHO Consultative Expert Working Group on R&D Financing. The revised proposal reflects recommendations put forward in this assessment including narrowing the fund's scope to supporting clinical trials and focusing on attracting new donors to global health R&D.